D espite the availability of newer oral anticoagulants that directly inhibit either Factor (F)Xa or thrombin, 1,2 warfarin continues to be used as an anticoagulant for stroke prevention in atrial fibrillation, secondary thromboprophylaxis in venous thromboembolism, and primary thromboprophylaxis in patients with mechanical heart valves. 3, 4 The major side effect of warfarin is bleeding and this can vary from minor bleeding, such as microscopic hematuria to more serious bleeding sometimes referred to as clinically relevant nonmajor bleeding (CRNMB), such as epistaxis or minor gastrointestinal bleeding, to life-threatening intracranial bleeding. [5] [6] [7] When major bleeding or CRNMB occurs it is necessary to temporarily discontinue the warfarin and administer the antidote, vitamin K. Under these circumstances, vitamin K is given intravenously (IV). 8, 9 In addition, repletion of the vitamin K factors using either plasma or prothrombin complex concentrates (PCCs) is often advocated for an immediate (short-lived) partial reversal. [10] [11] [12] [13] [14] [15] [16] [17] With the availability of a four-factor PCC, the use of plasma has declined and the four-factor PCC shown to be superior. 15, 17 However, use of a four-factor PCC can be associated with exposure to tens of thousands of blood donors, allergic reactions, and a risk of thrombosis, varying between 1.5 and 7.8%. 14, 16, 17 Hence, a conservative approach to the use of PCCs may be appropriate, restricting the use of four-factor PCCs to the more severe, limb or 
MATERIALS AND METHODS
The study was approved by the institutional review board at Roger Williams Hospital. With pharmacy data primarily, patients treated with IV vitamin K over a 2-year period (2015-2016) were identified. Some events were identified after a request for plasma was declined and vitamin K advised. For two such patients, serial samples were available which were frozen and assayed for FVII, F IX, and FX. For all events, data were collected for the pre-vitamin K INR, the INR(s) after IV administration, the time of the INR after IV administration, and the dose administered. A different set of leftover samples from patients with INRs of more than 4.0 were deidentified and studied using measures of activated partial thromboplastin time (aPTT), FV, FVIII, FVII, and FX. All clotting factor assays were performed using a chronometric one-stage method in an automatic analyzer (ACL Top 500, Instrumental Laboratory). Reagents were from Precision Biologic.
All data were deidentified and entered into a statistical database (Epistat) and descriptive statistics were derived. Statistical comparisons were performed using Mann-Whitney U tests, Kruskal-Wallis tests, paired t tests, or multilinear regression, as appropriate. Correlations were Pearson's correlation coefficient. Significance was considered a p value of less than 0.05.
RESULTS
A total of 41 patients given IV vitamin K doses were identified. Clinical data were obtained on 29 of these patients. Mean age was 73 6 11 years and 15 of 29 were female. The most common indication for warfarin was atrial fibrillation (19/29) followed by secondary thromboprophylaxis for venous thromboembolism (7/29). One patient was on warfarin for a mechanical heart valve and the indication was unclear in two patients. Eight patients presented with active bleeding, 17 patients required an urgent invasive procedure, and four required surgery. One patient was transfused with four-factor PCC and two with plasma. Thirteen patients received RBCs, but these were all actively bleeding patients or patients with bleeding who required a procedure, in most cases endoscopy. For those patients without bleeding who required an invasive procedure, there was no notation of any periprocedural bleeding and to our knowledge no procedure was canceled or deferred because of a persistently elevated INR. Five patients had two measures of the INR within 5 hours of IV vitamin K, making a total of 46 observations. A summary of the laboratory data and vitamin K doses for these 46 events are shown in Table 1 . There is a difference between the preadministration INR and the postadministration INR (p < 0.01). The mean delta INR (pre-post) was 4.2 6 3.4. As is evident, there is variation in the dose administered despite the recommendation. A total of 24 of 41 (60%) doses were 5 mg and 12 of 41 were 2 mg (30%). The rest were either 1 or 10 mg. In a multilinear regression analysis, the postadministration INR was related to the preadministration INR (p < 0.01) and the time (p 5 0.03), but not the dose (p 5 0.3).
A joined dot plot for these 46 events is shown in Fig. 1 . The majority of patients show large reductions in the INR within this 5-hour period and this is particularly true of patients with higher preinfusion INRs (arbitrarily > 4.0). Also evident in Fig. 1 is the intersubject variability, with some patients exhibiting a minor change in INR. To evaluate whether this "minor" change was time related (1-5 hr), the data are represented differently in a dot plot in Fig. 2 . In this plot, the time postinfusion was rounded up to the nearest hour. Achievement of an INR close to 2.0 or less appears time dependent in this cohort, with a 2-to 3-hour minimum threshold. There was no significant difference between the postinfusion INR at 3, 4, or 5 hours (p 5 0.2), suggesting that although time is a variable, intersubject variability in response to vitamin K is also an important variable and likely more important in the early hours after vitamin K administration.
For 22 patients, data were also available for INRs between 5 and 24 hours. These data were entered into the statistical software to generate a best-fit curve and equation. The postinfusion INR appears to conform to a second-order polynomial equation as follows and is largely independent of the preinfusion INR ( Fig. 1) :
where t is time in hours after infusion of the IV vitamin K and x is a variable related to the rate of synthesis of vitamin K factors (percent increase in clotting factor/hr), in particular FVII. (Fig. 1) likely relates to the observation that small increases in FVII (5%-10%) in patients with very high preinfusion INRs, and hence very low previtamin K infusion FVII (<10%), cause a large decline in the INR. As the FVII increases further over the next 5 to 24 hours, exceeding 15% to 20% in most patients, there is a lack of a correlation between the preinfusion INR and the postinfusion INR, as all postinfusion INR values cluster to a range between 1.5 and 2.5. 25 This is illustrated in Fig. 3 by two patients, each of whom received 5 mg of IV vitamin K. The patient in Fig. 3A had a preinfusion INR of 11.8 and a FVII of only 2%. This patient shows a rapid increase in FVII, achieving an approximate 50% increase over 10.5 hours (5%/hr) and an INR of 2.2 at this time point. The patient in Fig. 3B had a preinfusion INR of 5.5 and FVII of 8%. This patient shows a slower response, achieving an approximately 26% increase over 10 hours (2.6%/hr) but nevertheless an INR of 1.9 at this time point. Note the higher preinfusion F IX levels relative to autosomal factors in both these patients and the more rapid increase in FVII and F IX relative to FX. The early rate of increase (within 10 hr) in vitamin K clotting factors after IV vitamin K appears linear, suggesting a constant rate of factor synthesis.
To understand why the INR may be a poor predictor of clinical bleeding, even in patients with high INRs, 50 leftover samples from patients with an INR of more than 4.0 were studied with measures of clotting factors and the results are shown in Table 2 . Assays of FV were performed to exclude patients with liver disease, who are known to have high FVIII:C. 28, 29 As previously reported, 30 there is a poor correlation between FVII and the INR (r 5 -0.4, p < 0.01) in this range and even less so for FX (r 5 -0.2, p 5 0.08). Combining FVII and FX (arithmetic sum) makes this correlation a little better (r 5 -0.5, p < 0.01), but much of the variation remains unexplained. There is a difference between the FVII and FX levels (p < 0.01). Figure 4 shows the FVII and FX levels in relationship to the INR and illustrates the lack of any close relationship between these factors and the INR in this range of INRs. The FVIII:C levels in all of these patients were very high, most having FVIII:C levels of greater than 200%. Related to this, 46% of these samples (23/50) showed a normal aPTT. This likely explains the lack of correlation between the prothrombin time and the aPTT (r 5 0.2, p 5 0.1). Hence, in patients with high INRs ( > 4.0), the risk of bleeding may be attenuated for procedures or even surgery, as the high FVIII:C would promote better hemostasis in vivo and this population responds well, in general, and quickly to IV vitamin K (Fig. 1) .
DISCUSSION
Bleeding in patients taking warfarin is one of the most common causes for an emergency room visit 6 and a related problem presenting to the emergency department is a patient on warfarin who requires an urgent invasive procedure or surgery. 17 In most of these situations, partial reversal of the warfarin effect is required and this is achieved in all cases using the antidote IV vitamin K. The role of repletion of the vitamin K factors using plasma three-factor PCCs or four-factor PCCs is unclear, but these are commonly administered as a supplement to the antidote: four-factor PCCs have been shown to be preferable to plasma in this context. 15, 17 However, the clinical outcome in patients with CRNMB (non-life-threatening bleeding) or who require urgent procedures or surgery treated with IV vitamin K alone with or without allogeneic factor repletion has not been formally studied: The urgent achievement of hemostasis in bleeding patients or to prevent periprocedural bleeding has been the concern, but this could be exaggerated. Use of either plasma or PCCs is not without risk. Plasma may cause fluid overload, This study offers new information on the early response (<5 hr) to IV vitamin K showing substantial INR correction in a subpopulation of patients. To our knowledge only one previous small study of 12 patients has been published with a single measurement at 4 hours. 9 In this study, a fixed dose of 2 mg was used and the lowest INR observed was 2.7. These data differ from our data, possibly related to the dose or formulation in that a useful correction (INR 2.0-2.5) did not occur early after vitamin K. Furthermore, elevated levels of FVIII:C have previously been reported in patients on warfarin, 34, 35 which coupled with the rapid reduction in INR (Fig. 1 ) and the increase in F IX may act in concert to promote adequate hemostasis in vivo. There are also limitations to our study. This was a retrospective analysis of data with heterogeneity in indication for reversal and dose, despite the recommendation. However, this could also mimic more closely what might be expected to occur in emergency departments elsewhere. The question of optimal dosing of IV vitamin K for partial reversal of warfarin to achieve adequate hemostasis for bleeding control or an invasive procedure remains unknown. We chose a recommendation for 5 mg as it is close to the 3-mg dose used by Burbury and colleagues, 36 a dose that appeared to achieve the dual objective of periprocedural hemostasis without resistance to recommencement of warfarin. The slightly higher dose reflected our urgent situations rather than the elective procedures described by Burbury and colleagues. In addition, assessment of the adequacy of the vitamin K response alone is complicated by anatomic site bleeding, either spontaneous or provoked, and the relative contribution of this versus the hemostatic defect is always problematic to gauge. The transfusion of RBCs does not, therefore, indicate the failure of vitamin K therapy. It was, however, reassuring that in those cases requiring surgery or an invasive diagnostic procedure, there was no mention of excessive bleeding. The failure to observe excessive bleeding with an INR between 1.5 and 3.0 is consistent with previously published data on the performance of invasive procedures with INRs in the therapeutic range. [37] [38] [39] [40] We conclude that, contrary to a commonly held view, IV vitamin K as sole therapy for urgent warfarin reversal is capable of effecting a clinically meaningful reduction in the INR within 3 to 5 hours in some patients which may be satisfactory for the control of bleeding or performance of an invasive procedure. This approach could avoid unnecessary transfusion of either plasma or clotting factor concentrates and the related adverse events.
